biostudies-literatureSaad NMedical Research Council16008-16027https://www.ebi.ac.uk/biostudies/studies/S-EPMC5882314biostudies-literatureUnknown9(22)Inducing stable control of tumour growth by tumour reversion is an alternative approach to cancer treatment when eradication of the disease cannot be achieved. The process requires re-establishment of normal control mechanisms that are lost in cancer cells so that abnormal proliferation can be halted. Embryonic environments can reset cellular programmes and we previously showed that axolotl oocyte extracts can reprogram breast cancer cells and reverse their tumorigenicity. In this study, we analysed the gene expression profiles of oocyte extract-treated tumour xenografts to show that tumour reprogramming involves cell cycle arrest and acquisition of a quiescent state. Tumour dormancy is associated with increased P27 expression, restoration of RB function and downregulation of mitogen-activOncotargetCancer reversion with oocyte extracts is mediated by cell cycle arrest and induction of tumour dormancy.PMC5882314MR/N020979/1MR/L001047/1Johnson ADGiles TCSaad NClarke PAllegrucci CEmes RDAlberio RGrabowska AMfalseCancer reversion with oocyte extracts is mediated by cell cycle arrest and induction of tumour dormancy.Inducing stable control of tumour growth by tumour reversion is an alternative approach to cancer treatment when eradication of the disease cannot be achieved. The process requires re-establishment of normal control mechanisms that are lost in cancer cells so that abnormal proliferation can be halted. Embryonic environments can reset cellular programmes and we previously showed that axolotl oocyte extracts can reprogram breast cancer cells and reverse their tumorigenicity. In this study, we analysed the gene expression profiles of oocyte extract-treated tumour xenografts to show that tumour reprogramming involves cell cycle arrest and acquisition of a quiescent state. Tumour dormancy is associated with increased P27 expression, restoration of RB function and downregulation of mitogen-activ2018-01-01T00:00:00Z2018 Mar2026-05-02T02:42:24.408Z2019-03-26T23:29:11ZS-EPMC58823142966262310.18632/oncotarget.24664